Should we expand the concept of coronary heart disease equivalents?

Current Opinion in Cardiology

Volumn 29, Issue 4, 2014, Pages 389-395

  Katsiki, Niki ^a   Athyros, Vasilios G ^a   Karagiannis, Asterios ^a   Wierzbicki, Anthony S ^b   Mikhailidis, Dimitri P ^c  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Coronary heart disease equivalent; Erectile dysfunction; Metabolic syndrome; Nonalcoholic fatty liver disease; Obstructive sleep apnoea syndrome

Indexed keywords

ANASTROZOLE; DAUNORUBICIN; DOXORUBICIN; EXEMESTANE; GLUCOSE; IDARUBICIN; LETROZOLE; RALOXIFENE; RAZOXANE; TAMOXIFEN;

CHEMOTHERAPY; DISORDERS OF CARBOHYDRATE METABOLISM; ERECTILE DYSFUNCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATORY BOWEL DISEASE; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PERIODONTITIS; PRIORITY JOURNAL; RADIOTHERAPY; REVIEW; RISK FACTOR; SLEEP DISORDERED BREATHING; SYSTEMIC VASCULITIS; ADVERSE DRUG REACTION; ADVERSE EFFECTS; COMPLICATION; CORONARY DISEASE; MALE;

CORONARY DISEASE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HIV INFECTIONS; HUMANS; MALE; METABOLIC SYNDROME X; NON-ALCOHOLIC FATTY LIVER DISEASE; PERIODONTITIS; RADIOTHERAPY; RISK FACTORS;

EID: 84904733394     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0000000000000068     Document Type: Review

References (69)

1. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). J Am Med Assoc 2001;285:2486-2497.
2. Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult:2009 recommendations. Can J Cardiol 2009;25:567-579.
3. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-1818.
4. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325-331.
5. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013 (in press). Modern US guidelines on assessment and management of CVD risk.
6. National Clinical Guideline Centre. NICE guideline CG67 (update) lipid modification. NICE; 2014. http://www.nice.org.uk/guidance/index.jsp?action =download&o=66547. [Accessed 14 February 2014] UK guidelines of assessment and management of CVD risk.
7. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010;56:1113-1132.
8. Lim S, Shin H, Lee Y, et al. Effect of metabolic syndrome on coronary artery stenosis and plaque characteristics as assessed with 64-detector row cardiac CT. Radiology 2011;261:437-445.
9. Athyros VG, Ganotakis ES, Tziomalos K, et al. Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. Curr Med Res Opin 2010;26:713-719.
10. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-1645.
11. Luksiene DI, Baceviciene M, Tamosiunas A, et al. Comparison of four definitions of the metabolic syndrome and odds of ischemic heart disease in the Lithuanian urban population. Int J Public Health 2012;57:543-550.
12. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Characteristics other than the diagnostic criteria associated with metabolic syndrome: an overview. Curr Vasc Pharmacol 2013 (in press).
13. Athyros VG, Elisaf MS, Alexandrides T, et al. Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis. Angiology 2012;63:358-366.
14. Athyros VG, Ganotakis E, Kolovou GD, et al. Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospectiverandomized study in middle aged men and women. Curr Vasc Pharmacol 2011;9:647-657.
15. Michelotti GA, Machado MV, Diehl AM, et al. Nature reviews. Gastroenterol Hepatol 2013;10:656-665.
16. Treeprasertsuk S, Leverage S, Adams LA, et al. The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int 2012;32:945-950.
17. Bhatia LS, Curzen NP, Calder PC, Byrne CD. Nonalcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J 2012;33:1190-1200.
18. Sung KC, Ryan MC, Wilson AM. The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of nonobese Asian subjects. Atherosclerosis 2009;203:581-586.
19. Vanwagner LB, Bhave M, Te HS, et al. Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. Hepatology 2012;56:1741-1750.
20. Oni ET, Agatston AS, Blaha MJ, et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis 2013;230:258-267. Association of NAFLD with increased CVD risk.
21. Kim D, Choi SY, Park EH, et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology 2012;56:605-613.
22. Targher G, Chonchol M, Zoppini G, et al. Risk of chronic kidney disease in patients with nonalcoholic fatty liver disease: is there a link? J Hepatol 2011;54:1020-1029.
23. Sesti G, Fiorentino TV, Arturi F, et al. Association between noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver disease. PloS One 2014;9:e88569.
24. Corrado RL, Torres DM, Harrison SA. Review of treatment options for nonalcoholic fatty liver disease. Med Clin N Am 2014;98:55-72.
25. Eslami L, Merat S, Malekzadeh R, et al. Statins for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Cochrane Database Systematic Rev 2013;12:CD008623. Effect of lipid-lowering interventions in liver markers in NAFLD.
26. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010;376:1916-1922.
27. Tikkanen MJ, Fayyad R, Faergeman O, et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol 2013;168:3846-3852.
28. Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk). Br Med J 2001;322:15-18.
29. Shaye K, Amir T, Shlomo S, Yechezkel S. Fasting glucose levels within the high normal range predict cardiovascular outcome. Am Heart J 2012;164:111-116.
30. Anand SS, Dagenais GR, Mohan V, et al. Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study. Eur J Preventive Cardiol 2012;19:755-764.
31. DeFronzo RA, Abdul-Ghani M. Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am J Cardiol 2011;108:3B-24B.
32. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensivedose compared with moderate-dose statin therapy: a meta-analysis. J Am Med Assoc 2011;305:2556-2564.
33. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-742.
34. Waters DD, Ho JE, DeMicco DA, et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol 2011;57:1535-1545.
35. Waters DD, Ho JE, Boekholdt SM, et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. J Am Coll Cardiol 2013;61:148-152.
36. Thomas JJ, Ren J. Obstructive sleep apnoea and cardiovascular complications: perception versus knowledge. Clin Exp Pharmacol Physiol 2012;39:995-1003.
37. Wang X, Ouyang Y, Wang Z, et al. Obstructive sleep apnea and risk of cardiovascular disease and all-cause mortality: a meta-analysis of prospective cohort studies. Int J Cardiol 2013;169:207-214.
38. Dong JY, Zhang YH, Qin LQ. Obstructive sleep apnea and cardiovascular risk: meta-analysis of prospective cohort studies. Atherosclerosis 2013;229:489-495.
39. Somers VK, White DP, Amin R, et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College Of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation 2008;118:1080-1111.
40. Musso G, Cassader M, Olivetti C, et al. Association of obstructive sleep apnoea with the presence and severity of nonalcoholic fatty liver disease. A systematic review and meta-analysis. Obesity Revs 2013;14:417-431.
41. Jackson G, Boon N, Eardley I, et al. Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus. Int J Clin Pract 2010;64:848-857.
42. Gandaglia G, Briganti A, Jackson G, et al. A systematic review of the association between erectile dysfunction and cardiovascular disease. Eur Urol 2014;65:968-978. Association of erectile dysfunction with CVD risk.
43. Humphrey LL, Fu R, Buckley DI, et al. Periodontal disease and coronary heart disease incidence: a systematic review and meta-analysis. J Gen Intern Med 2008;23:2079-2086.
44. Holmlund A, Holm G, Lind L. Number of teeth as a predictor of cardiovascular mortality in a cohort of 7, 674 subjects followed for 12 years. J Periodontol 2010;81:870-876.
45. Costa TH, Neto JA, de Oliveira AE, et al. Association between chronic apical periodontitis and coronary artery disease. J Endod 2014;40:164-167.
46. Pressman GS, Qasim A, Verma N, et al. Periodontal disease is an independent predictor of intracardiac calcification. Bio Med Res Int 2013;2013:854340.
47. Teeuw WJ, Slot DE, Susanto H, et al. Treatment of periodontitis improves the atherosclerotic profile: a systematic review and meta-analysis. J Clin Periodontol 2014;41:70-79.
48. Meisel P, Kroemer HK, Nauck M, et al. Tooth loss, periodontitis and statins in a population-based follow-up study. J Periodontol 2013 (in press).
49. Ridker PM, Paynter NP, Rifai N, et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 2008;118:2243-2251.
50. Singh S, Loftus EV Jr. Cardiovascular risk in inflammatory bowel disease: it's a heartache! Gastroenterology 2013;145:1484-1486. Review of the association of IBD with CVD risk.
51. Gandhi S, Narula N, Marshall JK, Farkouh M. Are patients with inflammatory bowel disease at increased risk of coronary artery disease? Am J Med 2012;125:956-962.
52. Rogler G, Rosano G. The heart and the gut. Eur Heart J 2014;35:426-430.
53. Hollan I, Meroni PL, Ahearn JM, et al. Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev 2013;12:1004-1015. Review of the association of autoimmune disease with CVD.
54. Kulasegaram R, Peters BS, Wierzbicki AS. Dyslipidaemia and cardiovascular risk in HIV infection. Curr Med Res Opin 2005;21:1717-1725.
55. Lake JE, Currier JS. Metabolic disease in HIV infection. Lancet Infect Dis 2013;13:964-975.
56. Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med 2012;13:453-468.
57. Peters BS, Post F, Wierzbicki AS, et al. Screening for chronic comorbid diseases in people with HIV: the need for a strategic approach. HIV 2013;14(Suppl 1):1-11.
58. Lundgren JD, Battegay M, Behrens G, et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med 2008;9:72-81.
59. Vasiliadis I, Kolovou G, Mikhailidis DP. Cardiotoxicity and cancer therapy. Angiology 2013. (in press).
60. Schmitz KH, Prosnitz RG, Schwartz AL, Carver JR. Prospective surveillance and management of cardiac toxicity and health in breast cancer survivors. Cancer 2012;118:2270-2276.
61. Chavez-MacGregor M, Zhang N, Buchholz TA, et al. Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol 2013;31:4222-4228.
62. Aapro M, Bernard-Marty C, Brain EG, et al. Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Ann Oncol 2011;22:257-267.
63. Rosell J, Nordenskjold B, Bengtsson NO, et al. Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial. Br J Cancer 2011;104:899-902.
64. Filippatos TD, Liberopoulos EN, Pavlidis N, et al. Effects of hormonal treatment on lipids in patients with cancer. Cancer Treat Rev 2009;35:175-184.
65. Collins P, Mosca L, Geiger MJ, et al. Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors. Circulation 2009;119:922-930.
66. Jaworski C, Mariani JA, Wheeler G, Kaye DM. Cardiac complications of thoracic irradiation. J Am Coll Cardiol 2013;61:2319-2328.
67. Davis M, Witteles RM. Cardiac testing to manage cardiovascular risk in cancer patients. Semin Oncol 2013;40:147-155.
68. Fokkema M, den Hartog AG, Bots ML, et al. Stenting versus surgery in patients with carotid stenosis after previous cervical radiation therapy: systematic review and meta-analysis. Stroke 2012;43:793-801.
69. Wierzbicki AS. New directions in cardiovascular risk assessment: the role of secondary risk stratification markers. Int J Clin Pract 2012;66:622-630.